Eli Lilly announced its combo obesity regimen works better than the single drug. Groundbreaking stuff. Turns out two drugs beat one drug. Someone get the research team a calculator.
The company plans to add eloralintide to tirzepatide because apparently tirzepatide alone wasn't printing enough money. Phase 3 trials start at the end of the year. That gives retail traders approximately three months to misread the data, buy at the top, and blame market manipulation when their calls expire worthless.
Eloralintide is an amylin drug. Tirzepatide is the thing already making Lilly billions. Combining them boosts weight loss in mid-stage trials. This is the pharmaceutical equivalent of discovering that eating less food AND exercising works better than just eating less food. Revolutionary. Someone alert the Nobel committee.
Here's what happens next. Retail buys Lilly shares tomorrow morning because they saw the headline. They'll ignore that Phase 3 trials take years. They'll ignore that the combo regimen might fail. They'll ignore that the stock already priced in every obesity drug Lilly will ever make through 2087. None of that matters when you're trading on vibes and Reddit screenshots.
The mid-stage trial showed the combo worked. Lilly didn't release specific numbers in the headline because why spoil the surprise. Just trust them. Two drugs good. One drug less good. Math checks out.
Technical analysis says none of this matters. The stock goes up or down based on whether algos think other algos think retail thinks institutions are buying. The actual efficacy of eloralintide combined with tirzepatide has the same predictive value as a coin flip performed by a blindfolded toddler. But sure, let's all pretend reading this press release gave you an edge. I'm sure your $400 position will move the market.
Photo by on Unsplash
Leave a Comment